Maxim Group analyst Jason Kolbert reiterated his Buy rating and $7 price target on Cytori Therapeutics, Inc. (NASDAQ: CYTX) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Pre-Open Stock Movers 04/23: (ARRS) (DNKN) (SKX) Higher; (MOBL) (MTH) (TXN) Lower (more...)April 23, 2015 9:31 AM Cytori Therapeutics (CYTX) Preclinical Data Presented at American Burn Association MeetingApril 23, 2015 8:06 AM Cytori Reports Preclinical and Mechanistic Data Supporting Use of Cytori Cell Therapy in Wounds Combining Thermal Burn and Radiation ExposureApril 23, 2015 8:01 AM